oral KRAS(G12C) inhibitor

ph. III candidate for NSCLC

from de novo SBDD in SWII pocket

Cancer Discov.

Novartis, Basel, CH

JDQ443 chemical structure, oral KRAS(G12C) inhibitor (Novartis, Basel, CH)

Context. JDQ443 (Novartis Institute for Biomedical Research) is an oral KRASG12C inhibitor being developed for various advanced solid tumors. Despite accounting for 85% of RAS oncogenic mutations in all…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: